Thermo Fisher Scientific (TMO) Stock Price, News & Analysis

Company Overview

Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading provider of scientific instrumentation, reagents and consumables, and software and services to the global life sciences, biotechnology, pharmaceutical, clinical, academic, government, and industrial markets. The company’s portfolio encompasses analytical instruments such as mass spectrometers and chromatography systems, specialty diagnostics including immunoassays and molecular diagnostics, laboratory products ranging from pipettes to freezers, and comprehensive biopharma services covering development, manufacturing and clinical trial support.

Founded in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International, Thermo Fisher Scientific has grown organically and through strategic acquisitions to broaden its technology offerings and expand its global footprint. The company has integrated technologies such as genetic sequencing, cell and gene therapy support, and digital laboratory management to address evolving customer needs. Its focus on innovation is underscored by an extensive R&D network and collaborations with academic institutions and industry partners.

Thermo Fisher Scientific operates in more than 50 countries, with major research and manufacturing facilities across North America, Europe, Asia Pacific and Latin America. Its customer base spans large pharmaceutical companies, biotechnology firms, hospitals, universities, and government agencies, as well as industrial users in food safety, environmental testing and applied markets. The company leverages regional technical support teams, field service engineers and digital platforms to deliver customized solutions and ensure compliance with local regulations.

Under the leadership of President and Chief Executive Officer Marc N. Casper, Thermo Fisher Scientific emphasizes a culture of continuous improvement, sustainability and operational excellence. The executive team prioritizes investments in automation, digitalization, and green technologies to drive productivity and reduce environmental impact. Through its commitment to advancing science and supporting customers worldwide, the company aims to enable breakthroughs in research, diagnostics and biopharmaceutical production.

Key Stats

• Today's Range: $426.08 to $432.90
• 50-Day Range: $390.17 to $432.16
• 52-Week Range: $385.46 to $627.88
• Volume: 1.36 million shs
• Average Volume: 1.97 million shs
• Market Capitalization: $161.66 billion
• P/E Ratio: 25.12
• Dividend Yield: 0.40%
• Price Target: $604.05
• Consensus Rating: Moderate Buy

Thermo Fisher Scientific Stock Analysis - MarketRank™

Thermo Fisher Scientific scored higher than 100% of companies evaluated by MarketBeat, and ranked 13th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Thermo Fisher Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 16 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Thermo Fisher Scientific has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 9.79%

Earnings Growth

Earnings for Thermo Fisher Scientific are expected to grow by 9.79% in the coming year, from $23.28 to $25.56 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Thermo Fisher Scientific is 25.12, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.54.

Price to Earnings Ratio vs. Sector

The P/E ratio of Thermo Fisher Scientific is 25.12, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.47.

Price to Earnings Growth Ratio

Thermo Fisher Scientific has a PEG Ratio of 2.27. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Thermo Fisher Scientific has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.30% of the float of Thermo Fisher Scientific has been sold short.

Short Interest Ratio / Days to Cover

Thermo Fisher Scientific has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Thermo Fisher Scientific has recently increased by 3.59%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Thermo Fisher Scientific has a dividend yield of 0.41%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Thermo Fisher Scientific has been increasing its dividend for 8 years.

Dividend Coverage

The dividend payout ratio of Thermo Fisher Scientific is 10.09%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Thermo Fisher Scientific will have a dividend payout ratio of 6.73% next year. This indicates that Thermo Fisher Scientific will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -1.44

Percentage of Shares Shorted

1.30% of the float of Thermo Fisher Scientific has been sold short.

Short Interest Ratio / Days to Cover

Thermo Fisher Scientific has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Thermo Fisher Scientific has recently increased by 3.59%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.18

News Sentiment

Thermo Fisher Scientific has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 60 news articles for Thermo Fisher Scientific this week, compared to 35 articles on an average week.

Search Interest

40 people have searched for TMO on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.

MarketBeat Follows

Only 9 people have added Thermo Fisher Scientific to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Thermo Fisher Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $128,979.00 in company stock.

Percentage Held by Insiders

Only 0.33% of the stock of Thermo Fisher Scientific is held by insiders.

Percentage Held by Institutions

89.23% of the stock of Thermo Fisher Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TMO Stock Analysis - Frequently Asked Questions

How have TMO shares performed this year?

Thermo Fisher Scientific's stock was trading at $520.23 at the start of the year. Since then, TMO shares have decreased by 17.7% and is now trading at $428.25.

How were Thermo Fisher Scientific's earnings last quarter?

Thermo Fisher Scientific Inc. (NYSE:TMO) issued its quarterly earnings results on Wednesday, April, 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The company's revenue for the quarter was up .2% on a year-over-year basis.
Read the conference call transcript.

Is Thermo Fisher Scientific doing a stock buyback?

Thermo Fisher Scientific's Board of Directors authorized a stock buyback plan on Friday, November 15th 2024, which allows the company to repurchase $4,000,000,000 in shares, according to EventVestor. This means that the company could purchase up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board of directors believes its stock is undervalued.

Does Thermo Fisher Scientific have any subsidiaries?

Thermo Fisher Scientific subsidiaries include Henogen, Phinotex, Qiagen, Brammer Bio, HighChem, Gatan Inc, IntegenX, and more.

Who are Thermo Fisher Scientific's major shareholders?

Top institutional shareholders of Thermo Fisher Scientific include Confluence Investment Management LLC (0.02%), Neville Rodie & Shaw Inc. (0.02%), Jacobs & Co. CA and Legacy Wealth Management LLC MS. Insiders that own company stock include Marc N Casper, Stephen Williamson, Gianluca Pettiti, Jim P Manzi, Lisa P Britt, Michael A Boxer, Joseph R Holmes and Debora L Spar.
View institutional ownership trends.

How do I buy shares of Thermo Fisher Scientific?

Shares of TMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Thermo Fisher Scientific own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Thermo Fisher Scientific investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), The Goldman Sachs Group (GS), Illinois Tool Works (ITW) and NVIDIA (NVDA).

Company Calendar

• Record date for 4/15 Dividend: 3/14/2025
• Ex-Dividend for 4/15 Dividend: 3/14/2025
• Dividend Payable: 4/15/2025
• Last Earnings: 4/23/2025
• Record date for 7/15 Dividend: 6/13/2025
• Ex-Dividend for 7/15 Dividend: 6/13/2025
• Today: 7/04/2025
• Dividend Payable: 7/15/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:TMO
• CIK: 97745
• Web: www.thermofisher.com
• Phone: (781) 622-1000
• Fax: 781-622-1207
• Employees: 125,000
• Year Founded: 1956

Price Target and Rating

• Average Stock Price Target: $604.05
• High Stock Price Target: $686.00
• Low Stock Price Target: $450.00
• Potential Upside/Downside: +41.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): $17.05
• Trailing P/E Ratio: 25.12
• Forward P/E Ratio: 18.40
• P/E Growth: 2.27
• Net Income: $6.34 billion
• Net Margins: 15.19%
• Pretax Margin: 16.48%
• Return on Equity: 17.15%
• Return on Assets: 8.47%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 1.77
• Quick Ratio: 1.38

Sales & Book Value

• Annual Sales: $42.88 billion
• Price / Sales: 3.77
• Cash Flow: $30.07 per share
• Price / Cash Flow: 14.24
• Book Value: $129.54 per share
• Price / Book: 3.31

Miscellaneous

• Outstanding Shares: 377,490,000
• Free Float: 376,248,000
• Market Cap: $161.66 billion
• Optionable: Optionable
• Beta: 0.77